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Introduction
Chylothorax is a relatively uncommon cause of  pleural 
effusion (1). Lymph in the thoracic duct originates at the 
cisterna chyli and then passes from the abdomen into the 
mediastinum through the aortic hiatus. It then ascends su-
periorly in the posterior mediastinum and, at the level of  
T5-T6, the thoracic duct crosses to the left side to enter the 
superior mediastinum (1, 2). Chylous pleural effusions can 
be diagnosed on CT or MRI. The CT finding of  chylous 
effusions is typically a large unilateral effusion of  water 
attenuation and may demonstrate fat. The MRI findings 
may demonstrate high signal intensity on T1WI due to fat 
content. 
The causes of  chylous effusions can be congenital, trau-
matic, iatrogenic, malignant, idiopathic, infectious, or in-
flammatory (1, 2). Congenital chylothorax occurs more due 
to congenital malformations than to trauma during deliv-
ery (1). Chylothorax is predominantly seen following 
trauma or cardiothoracic surgery (2, 3). Traumatic injury 
to the thoracic duct is more common with penetrating 
trauma than blunt trauma, and is seen with hyperextension 
injuries (2, 4). Generally, an injury to the lower third of  the 
thoracic duct causes a right chylous effusion, to the upper 
two-thirds of  the thoracic duct causes a left chylous effu-
sion, and to the thoracic duct (as it crosses midline) causes 
bilateral chylous effusions. The thoracic duct can be ob-
structed from lymphadenopathy (including lymphoma, 
sarcoidosis, lung cancer, and tuberculosis) (5). We review 
the less common causes of  chylothorax, including lym-
phangioma, lymphangectasis, and lymphangioleiomyoma-
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tosis (LAM). Familiarity with these entities may lead to 
more prompt recognition and diagnosis. 
Case report
  A 21-year-old homosexual male presented with a chief  
complaint of  abdominal pain and bright red blood per rec-
tum over the preceding three weeks. He had nausea with-
out vomiting, bloody diarrhea, and 10 bowel movements 
per day. He denied any weight loss, fever, chest pain, or 
shortness of  breath. Colonoscopy with rectal biopsies 
demonstrated KS on pathology. The rectal bleeding was 
self-limited. He was managed for a left pleural effusion with 
a left pleural drain (Fig. 1). Laboratory testing confirmed 
that he was HIV-positive with a CD4 count of  12 cells/μL 
(427–1625 cells/μL). He was subsequently discharged 
home in stable condition. 
As an outpatient, a metastatic evaluation was performed 
starting with PET/CT (Fig. 2), which demonstrated exten-
sive lymphadenopathy. His newly diagnosed HIV was 
managed with Highly Active Antiretroviral Therapy 
(HAART), and chemotherapy was initiated for his KS as an 
outpatient. He then had excision of  a right level-five cervi-
cal lymph node that was positive for metastatic KS. Over 
the next five months, the patient experienced shortness of  
breath with upper- and lower-extremity edema responsive 
to diuretic therapy (Fig. 3). 
He was admitted five months later from his original ad-
mission for exacerbations of  these symptoms (Figs. 3, 4). 
He developed recurrent bilateral bloody chylous pleural 
effusions with progressive shortness of  breath and extensive 
peripheral lymphedema. He was tachycardiac with increas-
ing oxygen requirements requiring BiPAP, and eventually 
was intubated. 
The effusions were resistant to serial thoracentesis and 
pleural drains (Fig. 4). Multiple samples were sent for cytol-
ogy, which was negative for atypical and malignant cells. 
The location of  thoracic duct involvement by KS was to be 
assessed by lymphoscintigraphy before ligation of  the duct. 
There was such extensive inguinal lymphadenopathy that 
the radiotracer remained at the level of  the upper thighs 24 
hours post injection (Fig. 5). The thoracic duct at the cis-
terna chyli was found to be infiltrated with tumor on the 
chest CT (Fig. 6). The thoracic duct was unable to be safely 
ligated due to extensive infiltration of  the tumor; therefore, 
bilateral decortications with chest tube placement were 
performed instead in an attempt to control the chylous 
effusions. Bronchoalveolar lavage (BAL) demonstrated 
hemorrhagic secretions with erythema of  the bronchioles. 
An infectious evaluation was negative. The patient expired 
from cardiopulmonary arrest.
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Fig 2. PET/CT. Note 
extensive hypermeta-
bolic lymphadenopathy 
extending from the up-
per cervical regions 
throughout all nodal 
stations of the supra-
clavicular, axillary, me-
diastinal, hilar, retroperi-
toneal, mesenteric, iliac, 
and inguinal regions. 
Fig 1. Loculated left pleural effusion on original admission. 
Fig 3. Note interval progression of subcutaneous and mes-
enteric edema over five months from original admission (A) 
to readmission (B) due to infiltration of the cisterna chylis. 
Discussion
KS is a low-grade mesenchymal tumor involving blood 
and lymphatic vessels (6, 7). There are four types based on 
clinical presentation: classic, endemic (Africana), iatrogenic 
(typically renal allograft recipients) and AIDS-associated 
(epidemic). Human herpesvirus-8 (HHV8) infection has 
been linked along with other factors to the development of  
KS (6). KS is considered an AIDS-defining illness. 
Involvement of  visceral organs other than the lining of  
the alimentary tract is extremely rare (7, 8). Chylothorax is 
a rare manifestation of  KS involving the thoracic duct (9). 
KS with chylothorax was initially postulated to develop due 
to metastatic KS to the thoracic duct; more recent findings 
suggest that this may arise because of  in-situ KS in this 
region (10, 11). KS-related chylothoraces frequently de-
velop with concomitant upper-airway KS disease (9).
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Fig. 5. Lymphoscintigraphy. An interdermal injection between the web spaces of the toes was performed using Sulfur Colloid 
bound to the radiotracer Tech-99M. There is migration of Tech-99M filtered Sulfur Colloid radiotracer to the level of the upper 
thighs within one hour that persists at this level up to 24 hours post injection (arrows). No radiotracer is seen reaching the tho-
rax (arrowheads). 
Fig 4. Recurrent chylous pleural effusions status post-chest-tube placement and talc sclerotherapy. A. Increased right and 
loculated left pleural effusion on readmission. B. Status post-talc sclerotherapy and removal of right-sided chest tube with 
worsening loculated right pleural effusion. Note increased loculated and complex left pleural effusion with pleural thickening. 
Also note consolidative change involving almost the entire left lower lobe, lingual, and left upper lobe.
Pathophysiology/pathogenesis
Human herpes virus-8 (also known as Kaposi’s sarcoma-
associated herpes virus [KSHV]) was discovered by Chang 
and Moore and has been linked to the development of  KS 
as well as lymphoproliferative disorders, including primary-
effusion lymphoma and multicentric Castleman disease (12, 
13). Infection with KSHV is necessary for the development 
of  KS, although it is not sufficient by itself  (13). HIV co-
infection significantly increases the risk of  KS (13). KS has 
been found to be more common among persons who are at 
greater risk for sexually transmitted infections, which led to 
a search for an infectious etiology (14). KS cells have been 
screened for infectious agents, including cytomegalovirus, 
Epstein Barr virus, human papilloma virus, and myco-
plasma; these viral sequences are not uniformly found in 
KS. 
KSHV interacts and encodes for numerous molecular 
proteins that play a role in the pathogenesis of  KS, includ-
ing latency-associated nuclear antigen (LANA), viral G 
protein-coupled receptor, viral FLICE inhibitory protein, 
and viral IL-6 (12, 13). LANA acts as a transcriptional 
regulator binding to tumor-suppressing proteins p53 and 
retinoblastoma protein, which promotes the replication of  
the latent viral episome (12). The viral G protein-coupled 
receptor leads to proangiogenic signals by the upregulation 
of  hypoxia-inducible factor 1-alpha and the subsequent 
expression of  vascular endothelial growth factor (VEGF)-A 
and activation of  VEGF-receptor-2, which in turn activates  
PI3K-akt and the mammalian target of  rapamycin 
(mTOR) pathway (13). Viral FLICE inhibitory protein is 
associated with constitutively activated nuclear factor-κB, 
where it then activates a large number of  antiapoptotic 
genes (12). Viral IL-6 stimulates gp 130 coupled to the 
JAK-STAT pathway (13). It is secreted by KSHV-infected 
cells, allowing tumor cells to regulate their own growth 
through an autocrine pathway (13). A host of  other pro-
teins may play a role, including the HIV Tat protein, which 
has been shown to serve as a growth factor. In animal mod-
els, the replication of  the HIV virus may enhance the repli-
cation of  KSHV (13). HIV Tat promotes the migration and 
proliferation of  cytokine-activated endothelial cells, stimu-
lating KS growth (13). 
Clinical presentation
KS primarily affects the skin and causes disseminated 
disease in a variety of  organs. Skin lesions range from sev-
eral millimeters to several centimeters in size. The lesions 
are usually not painful or pruritic. 
Involvement of  visceral organs other than the lining of  
the alimentary tract is extremely rare. Gastrointestinal 
AIDS-related KS compromise is the most common visceral 
involvement in disseminated disease, being seen in up to 
50% of  patients (7). AIDS-related KS can affect any level 
of  the gastrointestinal tract from the oropharynx to the 
rectum, including the gallbladder (7). The duodenum is the 
most frequently affected site (7).
Pulmonary involvement with KS, in the majority of  
cases, occurs in conjunction with extensive mucocutaneous 
disease (15). Pulmonary involvement can be the initial 
manifestation (8). Affected patients can present with short-
ness of  breath, fever, cough, hemoptysis, or chest pain, or 
pulmonary involvement may be asymptomatic. When a 
new diagnosis of  KS is suspected in a patient with HIV 
infection, the degree of  HIV-related immunosuppression is 
assessed by measuring the CD4 count and HIV viral load 
(7). In patients with AIDS-related KS, the CD4 count ap-
pears to be the most important factor associated with the 
development of  KS. 
Imaging manifestations
KS can present with chylothorax. The typical pulmonary 
CT findings in AIDS-related KS are the presence of  bilat-
eral, ill-defined nodules in a peribronchovascular distribu-
tion (flame-shaped lesions representing tumor infiltration 
involving the bronchovascular bundles), areas of  ground-
glass opacities (representing edema and blood filling the 
airspace) surrounding nodules (the “halo sign”), peribron-
chovascular and interlobular septal thickening (representing 
edema or tumor infiltration), fissural nodularity, mediasti-
nal lymphadenopathy, pleural effusions (common), or pleu-
ral implants (rare) (6, 7, 16). The nodules correspond to 
proliferation of  neoplastic cells (6).
Diagnosis
The presumptive diagnosis of  AIDS-related pulmonary 
KS is often clinical (16). A tissue diagnosis is not required to 
establish the diagnosis of  pulmonary KS. Bronchoscopy is 
frequently performed to diagnose pulmonary KS with 
stains, culture, and cytology (which are frequently nega-
tive). The bronchoscopic appearance of  endobronchial KS 
is considered to be characteristic enough to allow a diagno-
sis (6). Parenchymal lesions may occur in the absence of  
tracheobronchial lesions detected by bronchoscopy. Endo-
bronchial KS lesions typically appear violaceous and are 
macular or papular, often at airway bifurications (8). Alveo-
lar hemorrhage is frequently diagnosed during BAL (7, 8). 
Endobronchial and transbronchial biopsies have a low di-
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Fig. 6. Cisterna Chyli infiltrated with tumor. The cisterna 
chyli is identified adjacent to the right side of the abdominal 
aorta and posterior to the inferior vena cava. The cisterna 
chyli appears enlarged and complex in attenuation (arrow). 
agnostic yield for KS, with the risk of  significant hemor-
rhage following biopsy (8, 17, 18). 
In the setting of  worsening pulmonary status, the pri-
mary diagnostic role of  thoracentesis may be to exclude an 
underlying infection caused by mycobacterium or fungus. 
KS lesions are found on the visceral but not parietal pleura 
(7). Pleural fluid cytology and biopsies are not helpful in 
diagnosis (19).
When chylous effusions are identified at thoracic CT, 
imaging findings allow lymphangioma, lymphangectasis, 
and LAM to be differentiated. Lymphangioma can present 
with chylothorax. The imaging findings of  lymphangioma 
are typically a homogeneous, thin-walled, well-defined, 
low-attenuating cystic mass, though increased attenuation 
occurs with high protein content, hemorrhage, or infection. 
Calcification or contrast enhancement is atypical. These 
lesions insinuate and cause displacement as they spread 
throughout the mediastinum, which also makes complete 
resection difficult (4). The most common location is the 
superior aspect of  the anterior mediastinum. Other rare 
locations include the pulmonary hila, pericardium, and 
intrapulmonary. 
Lymphangectasis can present with chylothorax. The im-
aging findings of  lymphangectasis include bilateral ground-
glass opacities, smooth interlobular septal thickening, 
marked pleural thickening, and mediastinal soft-tissue infil-
tration. The imaging findings resemble those of  LAM; 
however, lymphangectasis presents at a younger age with a 
much more progressive course (2, 4). LAM has dilated lym-
phatics like lymphangectasis but also has increased number 
of  lymphatics. 
LAM can present with chylothorax. The imaging find-
ings of  LAM include diffuse, thin-walled, uniform lung 
cysts (20). LAM is indistinguishable on imaging from tuber-
ous sclerosis complex. It can cause recurrent 
pneumothorax. 
Treatment
There is increasing evidence that HAART and an im-
proved immune response are associated with complete or 
partial regression of  KS lesions (6, 8, 16). Some studies 
showed that HAART alone can lead to stabilization and 
regression of  KS, often eliminating the need for chemora-
diation therapy (6, 16, 19). 
For asymptomatic pulmonary KS, typical treatment is 
initiated with ART without concomitant chemotherapy. For 
progression of  pulmonary KS after initiation of  ART or 
symptomatic pulmonary KS at presentation, systemic che-
motherapy is then generally indicated in addition to ART 
(11). Radiation therapy has been shown to improve symp-
tomatic control, though long-term survival remains poor 
(8).
Pleural effusions have been managed with repeat thora-
centesis in combination with ART and chemotherapy. If  
the pleural effusion rapidly reoccurs despite thoracentesis, 
an indwelling pleural catheter can be installed, or talc pleu-
rodesis performed. Chylous effusions respond poorly to 
chemical pleurodesis (21). 
Conclusion
KS is a low-grade mesenchymal tumor involving blood 
and lymphatic vessels. Kaposi’s sarcoma-associated herpes 
virus (KSHV) infection has been linked along with other 
factors to the development of  KS. KSHV interacts and 
encodes for numerous molecular proteins that play a role in 
the pathogenesis of  KS, including latency-associated nu-
clear antigen (LANA), viral G protein-coupled receptor, 
viral FLICE inhibitory protein, and viral IL-6. KS primar-
ily affects the skin and causes disseminated disease in a va-
riety of  organs. Involvement of  visceral organs other than 
the lining of  the alimentary tract is extremely rare. While 
the chylous pleural effusions of  KS may resemble other 
pulmonary diseases with chylous effusions at thoracic CT 
including lymphangioma, lymphangectasis, and LAM, 
differentiating features may allow for more prompt diagno-
sis and treatment. The presumptive diagnosis of  AIDS-
related pulmonary KS is often clinical. A tissue diagnosis is 
not required to establish the diagnosis of  pulmonary KS. 
There are a variety of  causes of  chylothorax. The primary 
finding is a near-water-attenuating pleural effusion on tho-
racic CT. It is the secondary findings of  chylothorax that 
can help differentiate the etiology.
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